US FDA rejects emergency use authorisation for Bharat Biotech’s Covaxin

The US Food and Drug Administration (FDA) has rejected Bharat Biotech’s proposal for an emergency use authorization (EUA) of its Covid vaccine Covaxin.

Ocugen, Bharat Biotech’s US partner, on June 10 said the company will now be seeking a full approval of Covaxin.

Earlier in June, Ocugen and Bharat Biotech announced that they have entered into an amendment to their co-development, supply, and commercialization agreement to expand Ocugen’s exclusive territory to commercialise Covaxin to now also include Canada.

Following US FDA’s rejection, the US biopharmaceutical company announced that tit will pursue submission of a biologics license application (BLA) for its COVID-19 vaccine candidate and the Company will no longer pursue an Emergency Use Authorization (EUA) for Covaxin.

“Although we were close to finalizing our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path. While this will extend our timelines, we are committed to bringing COVAXIN™ to the US. This differentiated vaccine is a critical tool to include in our national arsenal given its potential to address the SARS-CoV-2 variants, including the delta variant, and given the unknowns about what will be needed to protect US population in the long term,” said Dr Shankar Musunuri, chairman of the board, Chief Executive Officer, and co-founder of Ocugen.

Meanwhile, Bharat Biotech which is facing flak back in India has announced that the Phase 3 data of Covaxin’s trial will be published in July.

“It is critical to understand the Phase 3 data will first be submitted to CDSCO, followed by peer-reviewed journals, with a timeline of 3 months for publication, and as communicated earlier, COVAXIN Phase 3 results full trial data will be made public during July,” Bharat Biotech said.

“Once data from the final analysis of phase III studies are available, Bharat Biotech will apply for full licensure for COVAXIN,” it added.


Support Ethical Journalism. Support The Dispatch

The Dispatch is a sincere effort in ethical journalism. Truth, Accuracy, Independence, Fairness, Impartiality, Humanity and Accountability are key elements of our editorial policy. But we are still not able to generate great stories, because we don’t have adequate resources. As more and more media falls into corporate and political control, informed citizens across the world are funding independent journalism initiatives. Here is your chance to support your local media startup and help independent journalism survive. Click the link below to make a payment of your choice and be a stakeholder in public spirited journalism


The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies